natgillin/translations-raw huggingface dataset:
It is available as a spot-on solution in applicators of five different strengths for use on dogs of different weights.
Vectra 3D on müügil täpilahusena viie erineva tugevusega aplikaatorites kasutamiseks erineva kehakaaluga koertel.
It is available as a spot-on solution in applicators of two different strengths for use in cats of various bodyweights.
Ravimit turustatakse aplikaatorites kahe erineva tugevusega täpilahusena, mis on ette nähtud kasutamiseks eri kaaluga kassidel.
It is available as a suspension for injection (40 IU/ml).
Seda turustatakse süstesuspensioonina (40 IU/ml).
It is available as a suspension for injection that contains parts of the bacterium
Seda turustatakse bakteri Streptococcus pneumoniae osi sisaldava süstesuspensioonina.
It is available as a suspension for injection that contains some parts of inactivated (killed) influenza (flu) virus.
See on süstesuspensioon, mis sisaldab inaktiveeritud (hävitatud) gripiviiruse teatud osi.
It is available as a vial containing a powder which is dissolved before use to make up a solution for infusion (drip into a vein).
Seda turustatakse viaalidena, mis sisaldab pulbrit, millest valmistatakse infusioonilahus (veeni tilgutatav lahus).
It is available as a ‘spot-on’ solution in pipettes already filled with the correct amount needed to treat one dog depending on its weight.
Seda turustatakse täpilahusena eeltäidetud pipettides, milles on ühe koera ravimiseks vajalik Certifecti kogus olenevalt looma kehakaalust.
It is available as a ‘spot-on’ solution in pipettes filled with the appropriate amounts of indoxacarb and permethrin for dogs of different weights (75 mg/240 mg, 150 mg/480 mg,
Seda turustatakse täpilahusega eeltäidetud pipettides, milles on ühe koera ravimiseks vajalik indoksakarbi ja permetriini kogus, olenevalt looma kehakaalust (75 mg / 240 mg, 150 mg / 480 mg, 300 mg /
It is available as an inhalation powder in a portable inhaler device; each inhalation provides a fixed dose of the medicine.
Seda turustatakse inhalatsioonipulbrina kaasaskantavas inhalaatoris; iga inhalatsioon annab fikseeritud ravimiannuse.
It is available as an oily suspension, containing 0.9 mg/ml emodepside and 18 mg/ml toltrazuril.
Seda turustatakse õlisuspensioonina, mis sisaldab 0,9 mg/ml emodepsiidi ja 18 mg/ml toltrasuriili.
It is available as an oral solution (1 mg/ml) and tablets (0.5 mg, 1 mg and 2 mg).
Seda turustatakse suukaudse lahusena (1 mg/ml) ja tablettidena (0,5 mg, 1 mg ja 2 mg).
It is available as an oral suspension (200 mg/ml) for use in drinking water for pigs and chickens.
Seda turustatakse sigade ja kanade joogivees kasutatava suukaudse suspensioonina (200 mg/ml).
It is available as blue, oval tablets (150 or 300 mg).
Seda turustatakse siniste ovaalsete tablettidena (150 mg ja 300 mg).
It is available as capsules (0.5 mg).
Seda turustatakse kapslitena (0,5 mg).
It is available as capsules (133.3 mg lopinavir and 33.3 mg ritonavir), an oral solution (80 mg lopinavir and 20 mg ritonavir per millilitre) and tablets (100 mg lopinavir and 25 mg ritonavir; 200 mg lopinavir and 50 mg ritonavir).
Ravimit turustatakse kapslitena (133,3 mg lopinaviiri ja 33,3 mg ritonaviiri), suukaudse lahusena (80 mg lopinaviiri ja 20 mg ritonaviiri milliliitri kohta) ja tablettidena (100 mg lopinaviiri ja 25 mg ritonaviiri ning 200 mg lopinaviiri ja 50 mg ritonaviiri).
It is available as capsules (150 and 200 mg).
Seda turustatakse kapslitena (150 ja 200 mg).
It is available as capsules (2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg and 25 mg).
Ravimit turustatakse kapslitena (2,5 mg, 5 mg, 7,5 mg, 10 mg, 15 mg, 20 mg ja 25 mg).
It is available as capsules (200 and 400 mg).
Seda turustatakse kapslitena (200 ja 400 mg).
It is available as capsules (200 mg and 250 mg).
Seda turustatakse kapslitena (200 mg ja 250 mg).
It is available as capsules (200 mg) and tablets (500 mg).
Seda turustatakse kapslitena (200 mg) ja tablettidena (500 mg).
It is available as capsules (200 mg).
Seda turustatakse kapslitena (200 mg).
It is available as capsules (267 mg).
Seda turustatakse kapslitena (267 mg).
It is available as capsules (50 mg).
Seda turustatakse kapslitena (50 mg).
It is available as capsules (50, 100, 200 mg) and as tablets (600 mg).
Seda turustatakse kapslitena (50, 100, 200 mg) ja tablettidena (600 mg).
It is available as capsules (50, 100, 200 mg), as tablets (50, 200 and 600 mg), and as an oral solution (30 mg/ml).
Seda turustatakse kapslitena (50 mg, 100 mg, 200 mg), tablettidena (50, 200 ja 600 mg) ja suukaudse lahusena (30 mg/ml).
It is available as capsules (75, 110 and 150 mg).
Seda turustatakse kapslitena (75, 110 ja 150 mg).
It is available as capsules (white and brown: 5 mg; white: 10 mg).
Seda turustatakse kapslitena (valget ja pruuni värvi: 5 mg; valged 10 mg).
It is available as capsules containing a powder for inhalation (150 and 300 micrograms).
Seda turustatakse kapslitena, mis sisaldavad inhaleeritavat pulbrit (150 µg ja 300 µg).
It is available as capsules containing a powder for inhalation.
Seda turustatakse inhaleeritava pulbri kapslitena.
It is available as chewable tablets in five different strengths for use in dogs of different weights.
Seda turustatakse viie tugevusega närimistablettidena kasutamiseks eri kehamassiga koertel.
It is available as chewable tablets in four different strengths for use in dogs of different weights.
Seda turustatakse närimistablettidena neljas erinevas tugevuses kasutamiseks erineva kehamassiga koertel.
It is available as film-coated tablets (90, 180 and 360 mg) and as dispersible tablets (125, 250 and 500 mg).
Seda turustatakse õhukese polümeerkattega tablettidena (90, 180 ja 360 mg) ja dispergeeruvate tablettidena (125, 250 ja 500 mg).
It is available as immediate- release (200 mg) and prolonged-release tablets (50, 100 and 400 mg) and as an oral suspension (50 mg/5 ml).
Seda turustatakse toimeainet kiiresti vabastavate tablettidena (200 mg), toimeainet prolongeeritult vabastavate tablettidena (50 mg, 100 mg ja 400 mg) ja suukaudse suspensioonina (50 mg / 5 ml).
It is available as immediate- release tablets (0.088 mg, 0.18 mg, 0.35 mg, 0.7 mg and 1.1 mg) and prolonged-release tablets (0.26 mg, 0.52 mg, 1.05 mg, 1.57 mg, 2.1 mg, 2.62 mg and 3.15 mg).
Seda turustatakse toimeainet kiiresti vabastavate tablettidena (0,088 mg, 0,18 mg, 0,35 mg, 0,7 mg ja 1,1 mg) ja toimeainet prolongeeritult (pikaajaliselt) vabastavate tablettidena (0,26 mg, 0,52 mg, 1,05 mg, 1,57 mg, 2,1 mg, 2,62 mg ja 3,15 mg).
It is available as light green, oval tablets (30, 60 and 90 mg).
Seda turustatakse heleroheliste ovaalsete tablettidena (30 mg, 60 mg või 90 mg).
It is available as modified- release tablets (5 mg and 20 mg).
Ravimit turustatakse toimeainet modifitseeritult vabastavate tablettidena (5 mg ja 20 mg).
It is available as pink tablets (200 and 400 mg).
Seda turustatakse roosade tablettidena (200 ja 400 mg).
It is available as pink, capsule- shaped tablets (700 mg) and as an oral suspension (50 mg/ml).
Seda turustatakse roosade piklike tablettidena (700 mg) ja suukaudse suspensioonina (50 mg/ml).
It is available as prefilled syringes (12, 30 or 48 million units).
Seda turustatakse eeltäidetud süstaldena (12, 30 või 48 miljonit ühikut).
It is available as prolonged- release tablets (10 mg).
Seda turustatakse toimeainet prolongeeritult vabastavate tablettidena (10 mg).
It is available as round, white tablets (200 mg).
Seda turustatakse ümmarguste valgete tablettidena (200 mg).
It is available as round, yellow tablets (2.5, 5, 7.5, 10, 15 and 20 mg) and as round, yellow ‘orodispersible’ tablets (5, 7.5, 10, 15 and 20 mg).
Seda turustatakse ümmarguste kollaste tablettidena (2,5 mg, 5 mg, 7,5 mg, 10 mg, 15 mg ja 20 mg) ja ümmarguste kollaste suus dispergeeruvate tablettidena (5 mg, 7,5 mg, 10 mg, 15 mg ja 20 mg).
It is available as round, yellow tablets (90 mg).
Seda turustatakse ümmarguste kollaste tablettidena (90 mg).
It is available as soluble tablets (100 mg).
Ravimit turustatakse lahustuvate tablettidena (100 mg).
It is available as tablets (100 mg and 400 mg).
Pexion on müügil tablettidena (100 mg ja 400 mg).
It is available as tablets (100 mg, 200 mg or 400 mg) and as an oral suspension (40 mg/ml).
Seda turustatakse tablettidena (100 mg, 200 mg või 400 mg) ja suukaudse suspensioonina (40 mg/ml).
It is available as tablets (12.5, 25, 50 and 75 mg).
Seda turustatakse tablettidena (12,5, 25, 50 ja 75 mg).
It is available as tablets (123, 163, 204 and 245 mg) and as granules (33 mg/g).
Seda turustatakse tablettidena (123, 163, 204 ja 245 mg) ja graanulitena (33 mg/g).
It is available as tablets (150 mg) and as granules (50 mg and 75 mg) in a sachet.
Kalydecot turustatakse tablettidena (150 mg) ja kotikeses graanulitena (50 mg ja 75 mg).
It is available as tablets (2.5 mg / 850 mg or 2.5 mg / 1,000 mg).
Seda turustatakse tablettidena (2,5 mg / 850 mg või 2,5 mg / 1000 mg).
It is available as tablets (2.5, 10, 15 and 20 mg).
Seda turustatakse tablettidena (2,5 mg, 10 mg, 15 mg ja 20 mg).
It is available as tablets (2.5, 5 and 10 mg) and as dispersible tablets (2, 3 and 5 mg).
Seda turustatakse tablettidena (2,5 mg, 5 mg, 10 mg) ja dispergeeruvate tablettidena (2, 3 ja 5 mg).
It is available as tablets (2.5, 5 and 10 mg).
Seda turustatakse tablettidena (2,5, 5 ja 10 mg).
It is available as tablets (2.5, 5, 7.5, 10, 15 and 20 mg) and as ‘orodispersible’ tablets (5, 10, 15 and 20 mg).
Ravimit turustatakse tablettidena (2,5 mg, 5 mg, 7,5 mg, 10 mg, 15 mg ja 20 mg) ja suus dispergeeruvate tablettidena (5 mg, 10 mg, 15 mg ja 20 mg).
It is available as tablets (20, 50, 70, 80, 100 and 140 mg).
Seda turustatakse tablettidena (20, 50, 70, 80, 100 ja 140 mg).
It is available as tablets (240 mg).
Seda turustatakse tablettidena (240 mg).
It is available as tablets (25 mg).
Seda turustatakse tablettidena (25 mg).
It is available as tablets (25, 100 and 150 mg).
Seda turustatakse tablettidena (25, 100 ja 150 mg).
It is available as tablets (25, 100 and 200 mg).
Seda turustatakse tablettidena (25, 100 ja 200 mg).
It is available as tablets (250 mg).
Seda turustatakse tablettidena (250 mg).
It is available as tablets (400 mg).
Seda turustatakse tablettidena (400 mg).
It is available as tablets (50 mg; 100 mg; 150 mg; 200 mg), as a syrup (10 mg/ml) and as a solution for infusion (drip into a vein, 10 mg/ml).
Seda turustatakse tablettidena (50 mg, 100 mg, 150 mg ja 200 mg), siirupina (10 mg/ml) ja infusioonilahusena (veeni tilgutatav lahus, 10 mg/ml).
It is available as tablets (500 and 1,000 mg) and as an oral solution (100 mg/ml).
Seda turustatakse tablettidena (500 ja 1000 mg) ja suukaudse lahusena (100 mg/ml).
It is available as tablets (pink: 2 mg; orange: 4 mg; red-brown: 8 mg).
Seda turustatakse tablettidena (roosad 2 mg, oranžid 4 mg, punakaspruunid 8 mg).
It is available as tablets (yellow: 1 mg rosiglitazone and 500 mg metformin hydrochloride, and 2 mg rosiglitazone and 1,000 mg metformin hydrochloride; pale pink: 2 mg rosiglitazone and 500 mg metformin hydrochloride; pink: 4 mg rosiglitazone and 1,000 mg metformin hydrochloride).
Ravimit turustatakse tablettidena (kollased: 1 mg rosiglitasooni ja 500 mg metformiinvesinikkloriidi ning 2 mg rosiglitasooni ja 1000 mg metformiinvesinikkloriidi; kahvaturoosad: 2 mg rosiglitasooni ja 500mg metformiinvesinikkloriidi; roosad: 4 mg rosiglitasooni ja 1000 mg metformiinvesinikkloriidi).
It is available as tablets in five different strengths (6 mg for cats, and 5 mg, 10 mg, 20 mg and 40 mg for dogs) and as a solution for injection (20 mg/ml for dogs and cats).
Seda turustatakse viie eri tugevusega tablettidena (6 mg kassidele ning 5 mg, 10 mg, 20 mg ja 40 mg koertele) ja süstelahusena (20 mg/ml koertele ja kassidele).
It is available as tablets.
Truvadat turustatakse tablettidena.
It is available as triangular tablets (pink: 4 mg rosiglitazone and 4 mg glimepiride; red: 8 mg rosiglitazone and 4 mg glimepiride).
Ravimit turustatakse kolmnurksete tablettidena (roosad: 4 mg rosiglitasooni ja 4 mg glimepiriidi; punased: 8 mg rosiglitasooni ja 4 mg glimepiriidi).
It is available as two solutions, one containing the active substance human clottable protein (50 to 90 mg/ml), and the other containing the active substance human thrombin (800 to 1200 international units per millilitre).
Ravimit turustatakse kahe lahusena: ühe toimeaine on hüübiv inimvalk (50–90 mg/ml) ja teise toimeaine on inimtrombiin (800–1200 IU/ml).
It is available as two vials, one containing a white powder pellet and one containing a liquid.
Seda turustatakse kahe viaalina: üks sisaldab valge pulbri graanulit ja teine vedelikku.
It is available as white and light blue capsules (200 mg) and as an oral solution (10 mg/ml).
Seda turustatakse valge-helesiniste kapslitena (200 mg) ja suukaudse lahusena (10 mg/ml).
It is available as white capsule-shaped tablets.
Ravimit turustatakse valgete kapslikujuliste tablettidena.
It is available as white capsules (200 and 400 mg).
Seda turustatakse valgete kapslitena (200 ja 400 mg).
It is available as white soft capsules (75 mg).
Seda turustatakse valgete pehmete kapslitena (75 mg).
It is available as white tablets (200 mg, 400 mg, 600 mg and 800 mg).
Seda turustatakse valgete tablettidena (200 mg, 400 mg, 600 mg ja 800 mg).
It is available as white, teardrop- shaped tablets.
Seda turustatakse valgete pisarakujuliste tablettidena.
It is available as yellow-to- orange, capsule-shaped tablets (100 mg).
Seda turustatakse kapslikujuliste kollakas- oranžide tablettidena (100 mg).
It is available as ‘buccal tablets’ (tablets that dissolve in the mouth).
Seda turustatakse suus lahustuvate tablettidena.
It is available as ‘film-coated’ tablets (62.5 mg; 125 mg) and as dispersible tablets (32 mg).
Seda turustatakse õhukese polümeerkattega tablettidena (62,5 mg, 125 mg) ja dispergeeruvate tablettidena (32 mg).
It is available as ‘orodispersible’ tablets (5, 10, 15 and 20 mg).
Seda turustatakse suus dispergeeruvate tablettidena (5, 10, 15 ja 20 mg).
It is available as ‘oromucosal solution’ (a solution given in the side of the mouth, into the space between the gum and the cheek) in prefilled syringes.
Seda turustatakse suuõõnelahusena (suuõõnde, igeme ja põse vahelisse ruumi manustatav lahus) eeltäidetud süstaldes.
It is available in a pre-filled syringe (200 mg/ml).
Seda turustatakse eeltäidetud süstaldes (200 mg/ml).
It is available in a pre-filled syringe containing 6 mg pegfilgrastim.
Seda turustatakse eeltäidetud süstaldes, mis sisaldavad 6 mg pegfilgrastiimi.
It is available in blisters in pack sizes of 30 and 60 tablets and in glass bottles in pack sizes of 30, 60 ,100 and 200 film- coated tablets.
Tabletid on blisterpakendites, 30 ja 60 tabletti pakendis ja klaaspudelites, 30, 60, 100 ja 200 õhukese polümeerikattega tabletti pakendis.
It is available in pack sizes of 4 single-dose kits and 3 packs of 4 single-dose kits.
Seda on saadaval pakenditena, kus on 4 üheannuselist komplekti ja 3 pakendit 4 üheannuselise komplektiga.
It is available in packs containing 1, 4 or 12 pre-filled pens.
Pakend sisaldab 1, 4 või 12 pen-süstlit.
It is available in packs containing either 1 or 5 vials; each vial contains 1 mg or 4 mg of topotecan.
Pakendis on 1 või 5 viaali; viaalis on 1 mg või 4 mg topotekaani.
It is available in packs of 1 vial of 50 mL
Pakendis on üks 50 ml viaal.
It is available in packs of 1, 5 or 10 vials.
Pakendis on 1, 5 või 10 viaali.
It is available in packs of 4 vials.
Pakendis on 4 viaali.
It is available in packs of one or seven vials (not all pack sizes may be marketed).
Ühes pakendis on 1 või 7 viaali (kõik pakendi suurused ei pruugi olla müügil).
It is available in packs of:
Ravim on saadaval pakendis:
It is available in packs of:
See ravim on saadaval järgmistes pakendites:
It is available in pre-filled pens (6 mg/ml).
Seda turustatakse eeltäidetud pensüstaldes (6 mg/ml).
It is available in pre-filled syringes containing between 1,000 and 30,000 international units (IU) of the active substance, epoetin theta.
Seda turustatakse eeltäidetud süstaldes, mis sisaldavad 1000–30 000 rahvusvahelist ühikut (IU) toimeainet teetaepoetiini.
It is available in pre-filled syringes that contain between 1,000 and 40,000 international units (IU) of the active substance, epoetin alfa.
Seda turustatakse eeltäidetud süstaldes, mis sisaldavad 1000– 40 000 rahvusvahelist ühikut (IU) toimeainet alfaepoetiini.
It is available in pre-filled syringes that contain between 1,000 and 40,000 international units (IU) of the active substance, epoetin alfa.
Seda turustatakse eeltäidetud süstaldes, mis sisaldavad 1000–40 000 rahvusvahelist ühikut (IU) toimeainet alfaepoetiini.
It is available in prefilled syringes (250 mg).
Ravimit turustatakse eeltäidetud süstaldes (250 mg).
It is available in prefilled syringes containing between 1,000 and 40,000 international units (IU) of the active substance epoetin zeta.
Seda turustatakse eeltäidetud süstaldes, mis sisaldavad 1000–40 000 rahvusvahelist ühikut (IU) toimeainet dzeetaepoetiini.
It is available in prefilled syringes containing between 1,000 and 40,000 international units (IU) of the active substance, epoetin zeta.
Seda turustatakse eeltäidetud süstaldes, mis sisaldavad 1000–40 000 rahvusvahelist ühikut (IU) toimeainet dzeetaepoetiini.
It is available in prefilled syringes or in vials, each of which contains 60 mg denosumab.
Ravimit turustatakse eeltäidetud süstaldes ja viaalides, mis mõlemad sisaldavad 60 mg denosumaabi.
It is available in single- use vials containing 120 mg denosumab.
Seda turustatakse 120 mg denosumaabi sisaldavates ühekordselt kasutatavates viaalides.
It is available in single-dose containers and in multidose containers.
Instanyli turustatakse ühe- ja mitmeannuselistes mahutites.
It is available in strengths from 2,000 IU/ml to 20,000 IU/ml.
See on saadaval tugevusega 2 000–20 000 IU/ml.
It is available in two forms:
Seda turustatakse kahel kujul:
It is available in vials and in pre-filled syringes at various strengths ranging from 50 to 1,000 micrograms per millilitre.
Seda turustatakse viaalides ja eeltäidetud süstaldes tugevusega 50–1000 μg/ml.
It is available in vials or in prefilled syringes.
Seda turustatakse viaalides või eeltäidetud süstaldes.
It is believed that these symptoms are due to a recovery of the body’s immune system.
Arvatakse, et need sümptomid on tingitud organismi immuunsüsteemi taastumisest.
It is believed that these symptoms are due to an improvement in the body’s immune response, enabling the body to fight infections that may have been present with no obvious symptoms.
Arvatakse, et need sümptomid on tingitud organismi immuunvastuse paranemisest, mis võimaldab organismil võidelda infektsioonidega, mis võisid olemas olla ilma märgatavate sümptomiteta.
It is believed that these symptoms are due to an improvement in the body’s immune response, enabling the body to fight infections that may have been present with no obvious symptoms.
Arvatakse, et need sümptomid on tingitud organismi immuunvastuse paranemisest, võimaldades organismil võidelda infektsioonidega, mis võisid olla olemas ilma selgelt väljendunud sümptomiteta.
It is believed that these symptoms are due to an improvement in the body’s immune response, enabling the body to fight infections that may have been present with no obvious symptoms.
Arvatakse, et need sümptomid on tingitud organismi immuunvastuse paranemisest, võimaldades organismil võidelda nakkustega, mis on olnud olemas ilma väljendunud sümptomiteta.
It is believed that these symptoms are due to an improvement in the body’s immune response, enabling the body to fight infections that may have been present with no obvious symptoms.
Arvatakse, et need sümptomid tekivad keha immuunvastuse paranemise tõttu, võimaldades organismil võidelda infektsioonide vastu, mis võivad olla olnud olemas, kuid mille sümptomid pole kliiniliselt avaldunud.
It is believed that these symptoms are due to an improvement in the body’s immune response, enabling the body to fight infections that may have been present with no obvious symptoms.
Arvatakse, et need sümptomid tekivad organismi immuunvastuse tugevnemise tõttu, mis lubab organismil võidelda infektsioonidega, mis olid nähtavate sümptomiteta organismis eelnevalt olemas.
It is believed that these symptoms are due to an improvement in the body’s immune response, enabling the body to fight infections that may have been present with no obvious symptoms.
Arvatakse, et need sümptomid tekivad organismi immuunvastuse tugevnemise tõttu, mis lubab organismil võidelda infektsioonidega, mis olid organismis varem olemas ilma nähtavate sümptomiteta.
It is believed that these symptoms are due to an improvement in the body’s immune response, enabling the body to fight infections that may have been present with no obvious symptoms.
Usutavasti on nende sümptomite tekke põhjuseks organismi immuunvastuse paranemine, mis võimaldab organismil alustada võitlust infektsioonidega, mis võisid siiani olemas olla, ilma et oleks olnud märgatavaid sümptomeid.
It is believed that these symptoms are due to improvement in the body’s immune response, enabling the body to fight infections that may have been present with no obvious symptoms.
Arvatakse, et need sümptomid on tingitud organismi immuunvastuse paranemisest, võimaldades organismil võidelda nakkustega, mis on olnud olemas ilma avaldunud sümptomiteta.
It is best to have an interval as close as possible to 12 hours between doses, but this interval must be at least 6 hours.
Annuste vahe peaks olema võimalikult täpselt 12 tundi, kuid vähemalt 6 tundi.
It is best to measure your blood sugar level regularly, to get the maximum benefit of insulin delivery, and to make sure the pump is working properly.
Saamaks maksimaalset kasu insuliini manustamisest ja veendumaks, et pump töötab tõrgeteta on soovitatav mõõta veresuhkut regulaarselt.
It is best to take Avaglim with food, or just before food, usually with your first main meal of the day.
Kõige parem on Avaglim’i võtta söögi ajal või vahetult enne sööki, tavaliselt päeva esimese põhitoidukorra ajal.
It is best to take Avandamet with food, or just after food.
Kõige parem on Avandamet’i võtta söögi ajal või vahetult pärast sööki.
It is best to take HETLIOZ on an empty stomach as food can reduce the amount of the medicine that is absorbed into your body.
HETLIOZi on kõige parem võtta tühja kõhuga, sest toit võib vähendada organismi imenduva ravimi kogust.
It is best to take your tablet with a meal.
Parim on võtta tablett koos toiduga.
It is best to use Fuzeon at the same time each day.
Kõige parem on Fuzeon’i manustada iga päev samal kellaajal.
It is best to use the medicine at the same time each day, leaving 24 hours between each dose.
Oleks hea kui ravimit kasutataks iga päev samal ajal, jättes iga doosi vahele 24 tundi.
It is best to use your growth hormone regularly.
Kasvuhormooni on parem kasutada korrapäraselt.
It is bound predominantly to albumin and to a lower extent to -1 acid glycoprotein.
Ta seondub peamiselt albumiinile ja väiksemas osas -1 happe glükoproteiinile.
It is bound to the alpha-1- acid glycoprotein (AAG) and albumin, but has a higher affinity for AAG.
Amprenaviir seondub alfa-1-happe glükoproteiini (AAG) ja albumiiniga, kuid tal on suurem afiinsus AAG suhtes.
It is caused by a problem with your genes (called a “genetic mutation”) that affects the ability of cells in the eye to produce the energy they need to work normally, so they become inactive.
Seda põhjustab probleem teie geenides (geneetiline mutatsioon), mis kahjustab silma nägemisnärvi rakkude võimet toota normaalseks toimimiseks energiat, mistõttu need rakud muutuvad mitteaktiivseks.
It is caused by a thickening of the tissues under the skin of the palm that form ‘cords’ pulling down on the fingers.
Seda haigust põhjustab peopesa nahaaluste kudede kootumine, mille tagajärjel moodustuvad väädid, mis kõverdavad sõrmi.
It is caused by various factors including bleeding and poor absorption of iron from food in the inflamed gut of these patients.
Seda põhjustavad erinevad tegurid, sealhulgas verejooksud ja raua puudulik imendumine toidust patsiendi põletikulises sooles.